China Polypeptide (GREY:CHPN)

China Polypeptide Group became public via a reverse merger transaction on On November 13, 2009.

The Company, through its PRC-based indirect operating subsidiaries, Tallyho and Wuhan Anti-Aging is primarily engaged in the research and development, manufacturing and marketing of polypeptide-based nutritional supplements and health foods. Polypeptides are small molecular structures consisting of 10-50 amino acids that have been found to have nutritional value and support body functions such as regulating immunological functions in humans. We focus on enzyme engineering in order to produce macromolecular protein structures in the form of certain functional peptides for use as nutritional additives and supplements. Our key products include Polypeptide Protein Powder, which has been approved by the PRC State Food and Drug Administration (the “SFDA”), and Shenguo Polypeptide Capsules, which has been approved by the provincial Administration of Health of Hubei and is in the process of gaining SFDA approval. We currently manufacture and market lipid lowering soy peptide products in China, using our patented processing methods. Our products are sold to retail consumers directly and enterprises, through an established global network of distributors and retailers. Most of our products are manufactured in our owned and operated production facilities located in China. Some of our nutritional supplements and personal care products are manufactured for us through contractual relationships with other manufacturing companies, in accordance with our own proprietary formulations.